Identification of a nine‐gene panel as a prognostic indicator for recurrence with muscle‐invasive bladder cancer

Abstract

Background and Objectives Bladder cancer is one of the most common and highly recurrent cancers worldwide. Recurrence‐associated genes may potentially predict cancer recurrence. We aimed to construct a recurrence‐associated gene panel to improve the prognostic prediction of bladder cancer. Methods Based on DNA sequencing and clinical data from the TCGA‐BLCA project, we identified 10 potential driver genes significantly associated with recurrence of bladder cancer. We performed multivariable logistic regression analysis to construct an optimized recurrence prediction model with nine recurrence‐associated genes (EME1, AKAP9, ZNF91, PARD3, STAG2, ZFP36L2, METTL3, POLR3B, and MUC7) and clinical information as the independent variables. Results The area under the receiver operating characteristic (ROC) curve was 0.80 in this model, much higher than that of the baseline model (AUC = 0.73) and the same trend was also validated in its subset. Decision curve analysis also revealed that there is a significant net benefit gained by adding nine genes mutation to the baseline model. Furthermore, Kaplan‐Meier survival analysis showed that eight out of the nine genes (excluding MUC7) had good effects on the overall prognosis of patients. Conclusions This nine‐gene panel will most likely be a useful tool for prognostic evaluation and will facilitate the personalized management of patients with bladder cancer.

LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis

“…Next, targetscan website was employed to predict target gene of miR-490-3p. In numerous putative targets of miR-490-3p, POU3F2 was selected due to a crucial pro-tumor effect in numerous cancers [25,26]. The 3′UTR of POU3F2 (Fig.…”

Lower Mutant-Allele Tumor Heterogeneity is a Biomarker in FGFR3-Mutant Bladder Cancer for Better Prognosis

“…MIBCs have a more diverse mutation spectrum [25,26] and display high overall mutation rates similar to those of non-small cell lung cancers and melanoma [27]. MIBCs is also highly recurrent cancers worldwide [28] .…”

Roles of N6‐methyladenosine (m6A) RNA modifications in urological cancers

“…32 In addition, a nine-gene panel that included METTL3 was identified as a prognostic indicator for the recurrence of muscle invasive bladder cancer. 33 Yang et al 34 showed that METTL3 and ALKBH5 regulated m 6 A modification of the 3′-UTR of the oncogene CDCP1 mRNA and that YTHDF1 recognized m 6 A modification to promote CDCP1 translation in bladder cancer. Similarly, Jin et al 35 found that METTL3 and ALKBH5 regulated the m 6 A modification of the 3′-UTR of the oncogene ITGA6 mRNA and that YTHDF1/3 recognized m 6 A modification to promote ITGA6 translation in bladder cancer.…”